About: http://data.cimple.eu/news-article/76910ad2fa9453f866d6d7f01cfa35474a2911bcdffba464c46744da

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/76910ad2fa9453f866d6d7f01cfa35474a2911bcdffba464c46744da Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Russia's Sputnik V coronavirus vaccine is 92 percent effective according to initial test results, its developers said on Wednesday, as Moscow races against its competitors in the West. The calculations were based on results from 16,000 individuals who received both doses of the vaccine, Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement. "The Sputnik V vaccine had an efficacy rate of 92 percent after the second dose," the statement said, after 20 of the volunteers -- some of whom were given the placebo -- tested positive for coronavirus. The adenovirus vector-based vaccine uses modified viruses of the regular flu. Some of those vaccinated experienced "pain at the injection site, flu-like syndrome including fever, weakness, fatigue and headache," the statement said. Russia in August became the first country to register a coronavirus vaccine but did so ahead of the large-scale clinical trials that are still underway. Forty thousand volunteers at 29 medical centres are taking part in the third and final phase of Sputnik V trials. In September, the vaccine was separately administered to medics and other at-risk people working in Russian hospitals, demonstrating an efficacy rate of "over 90 percent," the statement said. Regional authorities in Siberia's Altai region on Tuesday said that at least three medics out of the 42 that received the vaccine had contracted the virus. Wednesday's statement added that the interim research data will be published in one of the world's "leading peer-reviewed medical academic journals". Observation of trial participants will continue for six months, after which the full clinical trial report will be presented, it added. The statement said that RDIF, which is funding development of Sputnik V, will provide research data to countries that are interested in purchasing the Russian vaccine. Overseas trials are also taking place in the UAE, Venezuela, Belarus and other countries, the statement said. The announcement of Sputnik V's interim results comes days after Western vaccine developers Pfizer and BioNTech said that their vaccine was more than 90 percent effective. acl/jbr/mbx
schema:headline	Russia says Sputnik V virus vaccine 92% effective
schema:mentions	The Statement (film) Siberia Adenoviridae Fatigue Peer review Headache Belarus Clinical trial Placebo Fever Sputnik 1 United Arab Emirates Pain Moscow Influenza Venezuela Russia Russian language Virus Pfizer Vaccine Severe acute respiratory syndrome coronavirus 2 Influenza-like illness Russian Direct Investment Fund Anterior cruciate ligament
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-11-11 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	82 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software